Cadence Pharmaceuticals

Duncan-Williams reports that, with regard to Cadence Pharmaceuticals Inc. (NASDAQ: CADX), “after reviewing the 10K and speaking with management we have realized that our first year ramp curve is overly aggressive.” “Management indicated that stocking a hospital typically corresponds to a single...

Oppenheimer is reiterating its Underperform rating on shares of Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) on expectations for a softer than expected OFIRMEV launch. “We anticipate consensus revenues for OFIRMEV will come down over 2011, pressuring shares,” Oppenheimer writes. “While CPIX's...

On 11/2, Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) announced the approval of OFIRMEV, the company's IV acetaminophen product, Oppenheimer reports. Oppenheimer believes that the market for OFIRMEV is overestimated. “Additionally, we believe a generics company could immediately file a paragraph IV...